Truist initiated coverage of Janux Therapeutics (JANX) with a Buy rating and $100 price target The firm believes the company’s masking platform has the potential to overcome the limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. Janux ‘s lead asset, JANX007, has “best-in-class potential” in prostate cancer and a key Phase 1 data readout in the second half of 2025, the analyst tells investors in a research note. Truist believes JANX008 represents upside potential for the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements
- Janux Therapeutics resumed with a Buy at Stifel
- Janux Therapeutics initiated with a Buy at Guggenheim
- Piper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potential
- Janux Therapeutics initiated with an Overweight at Piper Sandler